Andes Hantavirus Vaccine Development Stalled Over Funding; Chilean Scientists Halt Human Trial Preparations

A vaccine development effort in Chile targeting the Andes hantavirus—the strain responsible for the recent MV Hondius outbreak—has stalled due to lack of funding. Scientists had achieved early success in animal models and were preparing to transition the candidate vaccine to human testing when financial constraints forced a pause in development. The setback occurs amid broader disruptions to global vaccine policy, including U.S. funding cuts to international health organizations and personnel changes at domestic agencies including the FDA and NIAID. The article contextualizes the Andes virus vaccine challenge within wider discussions of vaccine policy, ACIP charter revisions, and regulatory leadership transitions.